Drug Trial Radar · NCT07226882
A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults
Last checked: Nov 19, 2026Latest source record: May 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
207
Actual
Start
Nov 19, 2025
Primary completion
Jan 27, 2028
Study completion Jan 27, 2028
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 12, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 44 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn about the safety and effects of the Lyme disease vaccine (called VLA15) when given at different time points. This study is seeking participants who: * are generally healthy and between 18 and 44 years of age, * have never had a vaccine for Lyme disease before, * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners, and * are not pregnant or breastfeeding and do not plan to become pregnant while receiving the study vaccine. All participants in this study will receive a total of 5 doses through a shot in the upper arm. Four doses will be the study vaccine (VLA15), and 1 dose will be saltwater. The study will compare the experiences of people receiving the study vaccine at different time points. This will help see if the study vaccine is safe and will help understand its effect on the body. Participants will take part in this study for about 2 years. During this time, the participants will have 11 planned visits - 8 will be at the study clinic and 3 will be done over the phone. The clinic visits may include having a health check, giving a small amount of blood (about 20 mL or 4 teaspoons), and getting the study vaccine or saltwater as a shot.
Conditions
- Lyme Borreliosis
Interventions
VLA15Biological
Participants will receive IM injection of 6-valent OspA-based Lyme disease vaccine
PlaceboBiological
Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Geometric Mean Concentration (GMC) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG)Time frame: At 1 month after the fourth VLA15 dose
- Geometric Mean Fold Rise (GMFR) of Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) ConcentrationsTime frame: Before the first dose to 1 month after the fourth VLA15 dose
- Sero-Response Rate Based on Anti-Outer Surface Protein A (OspA) Immunoglobulin G (IgG) Concentrations.Time frame: Before the first dose to 1 month after the fourth VLA15 dose
- Percentage of Participants With Local Reactions For Each GroupTime frame: Within 7 days after each vaccination
- Percentage of Participants With Systemic Events For Each GroupTime frame: Within 7 days after each vaccination
- Percentage of Participants With Adverse Events (AEs) For Each GroupTime frame: Within 1 month after each vaccination
- Percentage of Participants With Serious Adverse Events (SAEs) For Each GroupTime frame: From the time the participant provides informed consent up to approximately 6 months after the last vaccination
- Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) For Each GroupTime frame: From the time the participant provides informed consent up to approximately 6 months after the last vaccination
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
IMA Clinical Research Warren
Warren Township, New Jersey
Smith Allergy and Asthma Specialists
Cortland, New York
Smith Allergy & Asthma Specialists
Horseheads, New York
Preferred Primary Care Physicians, Preferred Clinical Research (Ofc 18)
Pittsburgh, Pennsylvania
Northeast Clinical Trials Group
Scranton, Pennsylvania
Preferred Primary Care Physicians
Uniontown, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.